TMS Co

TMS Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TMS Co (4891.T) as of Nov 3, 2026 is -836.37 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -907.79 M JPY — a change of -7.87% (higher).

EBITDA

-836.37 MJPY

YoY

-7.87%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TMS Co is 2026 -836.37 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TMS Co was 2025 -907.79 M JPY. It decreases by -7.87% higher compared to the previous year.

The TMS Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
-717.15 M JPY
Jan 1, 2022
1.14 B JPY
Jan 1, 2023
-515.01 M JPY
Jan 1, 2024
-937.86 M JPY
Jan 1, 2025
-907.79 M JPY
Jan 1, 2026
-836.37 M JPY
The TMS Co EBITDA history
YEAREBITDAYoY
-836.37 MJPY-7.87%
-907.79 MJPY-3.21%
-937.86 MJPY+82.10%
-515.01 MJPY-145.34%
1.14 BJPY-258.39%
-717.15 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TMS Co is -836.37 M JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TMS Co changed from -907.79 M JPY to -836.37 M JPY, representing a -7.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) TMS Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — TMS Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — TMS Co